ArticleJournal of enzyme inhibition and medicinal chemistry2025

Selisistat, a SIRT1 inhibitor, enhances paclitaxel activity in luminal and triple-negative breast cancer: in silico, in vitro, and in vivo studies.

Anna Wawruszak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.